Argenx enters into agreement to acquire priority review voucher

Amsterdam, the netherlands – november 30, 2022 – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a u.s. food and drug administration (fda) priority review voucher (prv) for $102 million. a prv entitles the holder to fda priority review of a single biologics license application (bla), which reduces the target review period and may lead to an expedited approval.
ARGX Ratings Summary
Quant
ARGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score